RETIRED: Canadian Contraception Consensus—Update on Depot Medroxyprogesterone Acetate (DMPA)

Fisher, 2004, The 2002 Canadian contraception study: part 1, J Obstet Gynaecol Can, 26, 580, 10.1016/S1701-2163(16)30377-2

Schwallie, 1973, Contraceptive use—efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90days, Fertil Steril, 24, 331, 10.1016/S0015-0282(16)39669-8

Nelson, 1996, Counseling issues and management of side effects for women using depot medroxyprogesterone acetate contraception, J Reprod Med, 41, 391

Polaneczky, 1996, Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population, Fam Plann Perspect, 28, 174, 10.2307/2136195

Betsey, 1991, Task Force on Long-Acting Systemic Agents for Fertility Regulation, Menstrual bleeding patterns in untreated women and with long-acting methods of contraception, Adv Contracept, 7, 257, 10.1007/BF01849416

Said, 1986, Contraception, 34, 223, 10.1016/0010-7824(86)90004-1

Sangi-Haghpeykar, 1996, Experiences of injectable contraceptive users in an urban setting, Obstet Gynecol, 88, 227, 10.1016/0029-7844(96)00194-9

Schwallie, 1974, The effect of depo-medroxyprogesterone acetate on pituitary and ovarian function, and the return of fertility following its discontinuation: a review, Contraception, 10, 181, 10.1016/0010-7824(74)90073-0

Pardthaisong, 1984, Return of fertility after use of the injectable contraceptive Depo-Provera: up-dated data analysis, J Biosoc Sci, 16, 23, 10.1017/S0021932000014760

Fotherby, 1986, Return of fertility in women discontinuing injectable contraceptives, J Obstet Gynaecol, 6, S110, 10.3109/01443618609081724

Gbolade, 1998, Bone density in long term users of depot medroxyprogesterone acetate, Br J Obstet Gynaecol, 105, 790, 10.1111/j.1471-0528.1998.tb10211.x

Cromer, 2003, Bone mineral density in adolescent and young adult women on injectable or oral contraception, Curr Opin Obstet Gynecol, 15, 353, 10.1097/00001703-200310000-00002

Cundy, 1998, Spinal bone density in women using depot medroxyprogesterone contraception, Obstet Gynecol, 92, 569

Scholes, 1999, Bone mineral density in women using depot medroxyprogesterone acetate for contraception, Obstet Gynecol, 93, 233

Berenson, 2001, A prospective, controlled study of the effects of hormonal contraception on bone mineral density, Obstet Gynecol, 98, 576

Scholes, 2002, Injectable hormone contraception and bone density: results from a prospective study, Epidemiology, 13, 581, 10.1097/00001648-200209000-00015

Busen, 2003, Bone mineral density in a cohort of adolescent women using depot medroxyprogesterone acetate for one to two years, J Adolesc Health, 32, 257, 10.1016/S1054-139X(02)00567-0

Scholes, 2005, Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception, Arch Pediatr Adolesc Med, 159, 139, 10.1001/archpedi.159.2.139

Clark, 2004, Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate, Fertil Steril, 82, 1580, 10.1016/j.fertnstert.2004.04.064

Cromer, 2004, Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls, J Adolesc Health, 35, 434, 10.1016/j.jadohealth.2004.07.005

Lara-Torre, 2004, Bone mineral density in adolescent females using depot medroxyprogesterone acetate, J Pediatr Adolesc Gynecol, 17, 17, 10.1016/j.jpag.2003.11.017

Orr-Walker, 1998, The effect of past use of the injectable contraceptive depot meroxyprogesterone acetate on bone mineral density in normal post-menopausal women, Clin Endocrinol(Oxf), 49, 615, 10.1046/j.1365-2265.1998.00582.x

Pettiti, 2000, Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. The WHO Study of Hormonal Contraception and Bone Health, Obstet Gynecol, 95, 736

Sowers, 1993, Changes in bone density with lactation, JAMA, 269, 3130, 10.1001/jama.1993.03500240074029

US Food and Drug Administration. 2004. Available at: http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01325.html Accessed September 6, 2005.

Health Canada. Drugs and Health Products, Advisories, Warnings and Recalls for Health Professionals. Available at: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/depo-provera_2_hpc-cps_e.html . Accessed September 6, 2005.

World Health Organization. WHO Statement on Hormonal Contraception and Bone Health. 2005. Available at: http://www.who.int/reproductive-health/family_planning/bone_health.html Accessed September 6, 2005.

Khan, 2002, Standards and guidelines for performing central dual X-ray densitometry from the Canadian Panel of International Society for Clinical Densitometry, J Clin Densitom, 5, 435, 10.1385/JCD:5:4:435

Cundy, 2003, A randomized controlled trial of estrogen replacement therapy in 1ong-term users of depot medroxyprogesterone acetate, J Clin Endocrinol Metab, 88, 78, 10.1210/jc.2002-020874

Cromer, 2005, Double-blinded randomized controlled trial of estrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception, Am J Obstet Gynecol, 192, 42, 10.1016/j.ajog.2004.07.041

Woolf, 1994, xxxvi